MonumenTAL-1: Talquetamab in Relapsed/Refractory MM
Donna Catamero, ANP-BC, OCN, CCRC, reviews findings from the MonumenTAL-1 study and the panel provides its impressions of the results.
This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Results from the phase 1/2 MonumenTAL-1 trial (NCT03399799) led to FDA approval of talquetamab, a GPRC5D-targeting bispecific antibody, for relapsed/refractory multiple myeloma (MM) after at least 3 prior lines including proteasome inhibitors, immunomodulators, and anti-CD38 antibodies. Patients received step-up dosing of talquetamab 0.4 mg/kg weekly, 0.8 mg/kg every other week, or either schedule after prior T-cell redirection therapy. Overall response rates were 72% to 74% (65% after prior therapy), very good partial response or better rate was 65% (55% after prior therapy), median progression-free survival was 5.1 to 14.2 months, and 12-month duration of response rates for complete response were 79% to 90%. Adverse events included cytokine release syndrome, dysgeusia, dermatologic toxicity, and cytopenias. Infection rates were 59% to 73% (higher after prior therapy).
Rodriguez found talquetamab efficacy and durability comparable to BCMA-directed treatments. Usmani welcomed talquetamab while noting the need for sequencing data between GPRC5D and BCMA targets. Limitations include lack of patients with high-risk disease features to inform effectiveness in these groups.
Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.
